ASH 2023 | Predictors of poor response to azacitidine, venetoclax, and magrolimab in TP53-mutated AML
Hussein Abbas
• 9 Dec 2023
Hussein Abbas, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the single-cell characterization of response to azacitidine, venetoclax, and magrolimab treatment for patients with TP53-mutated acute myeloid leukemia (AML), currently being assessed in a clinical trial (NCT04435691). Erythroid differentiation phenotype, presence of immune cells, and an inflammatory bone marrow microenvironment were all factors that contributed to a lack of response. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
